JP2023511255A - ＴＧＦ－β阻害剤及びその使用 - Google Patents

ＴＧＦ－β阻害剤及びその使用 Download PDF

Info

Publication number
JP2023511255A
JP2023511255A JP2022539654A JP2022539654A JP2023511255A JP 2023511255 A JP2023511255 A JP 2023511255A JP 2022539654 A JP2022539654 A JP 2022539654A JP 2022539654 A JP2022539654 A JP 2022539654A JP 2023511255 A JP2023511255 A JP 2023511255A
Authority
JP
Japan
Prior art keywords
tgfβ
tumor
inhibitor
antibody
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022539654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023511255A5 (https=
Inventor
アシッシュ カルラ
トーマス シュルフ
アダム フォーゲル
クリストファー ブルックナー
アラン バックラー
コンスタンス マーティン
シ ツアン リー―ヘフリッヒ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scholar Rock Inc
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of JP2023511255A publication Critical patent/JP2023511255A/ja
Publication of JP2023511255A5 publication Critical patent/JP2023511255A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2022539654A 2020-01-11 2021-01-11 ＴＧＦ－β阻害剤及びその使用 Pending JP2023511255A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202062959909P 2020-01-11 2020-01-11
US62/959,909 2020-01-11
US202062981083P 2020-02-25 2020-02-25
US62/981,083 2020-02-25
US202062704915P 2020-06-03 2020-06-03
US62/704,915 2020-06-03
US202062705134P 2020-06-12 2020-06-12
US62/705,134 2020-06-12
US202063111530P 2020-11-09 2020-11-09
US63/111,530 2020-11-09
PCT/US2021/012969 WO2021142448A2 (en) 2020-01-11 2021-01-11 Tgf-beta inhibitors and use thereof

Publications (2)

Publication Number Publication Date
JP2023511255A true JP2023511255A (ja) 2023-03-17
JP2023511255A5 JP2023511255A5 (https=) 2024-01-05

Family

ID=74595383

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022539654A Pending JP2023511255A (ja) 2020-01-11 2021-01-11 ＴＧＦ－β阻害剤及びその使用

Country Status (6)

Country Link
US (1) US20230050148A1 (https=)
EP (1) EP4087659A2 (https=)
JP (1) JP2023511255A (https=)
AU (1) AU2021205440A1 (https=)
CA (1) CA3166328A1 (https=)
WO (1) WO2021142448A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53125A (fr) 2018-07-11 2021-05-19 Scholar Rock Inc Inhibiteurs de tgf?1 sélectifs selon l'isoforme à affinité élevée
EP4348260A2 (en) * 2021-06-03 2024-04-10 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
CA3227334A1 (en) * 2021-07-28 2023-02-02 Tiumbio Co., Ltd. Pharmaceutical composition for preventing or treating tumor, and use thereof
AU2023219697A1 (en) * 2022-02-09 2024-08-22 Exelixis, Inc. Multispecific binding agents and uses thereof.
EP4587477A2 (en) * 2022-09-14 2025-07-23 Ohio State Innovation Foundation Methods for reprograming exhausted t cells and boosting immune checkpoint blockade therapy for cancer
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer
CN119476445B (zh) * 2025-01-06 2025-04-11 杭州宇泛智能科技股份有限公司 基于大小模型协同智能的模型优化方法及系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018129329A1 (en) * 2017-01-06 2018-07-12 Scholar Rock, Inc. ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF
JP2019509737A (ja) * 2016-03-11 2019-04-11 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． ＴＧＦβ１結合性免疫グロブリンおよびその使用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
NZ331688A (en) 1996-03-28 2000-02-28 Univ Johns Hopkins Soluble divalent and multivalent heterodimeric analogs of proteins
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
KR100919593B1 (ko) 2000-06-29 2009-09-29 아보트 러보러터리즈 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물
BRPI0608376A8 (pt) 2005-04-22 2018-10-16 Lilly Co Eli composição de ligação, método de uso de uma composição de ligação, e, kit de detecção
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
TW201006485A (en) 2008-06-03 2010-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
DK2780368T3 (en) 2011-11-14 2018-02-05 Regeneron Pharma COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A
US9518112B2 (en) 2012-03-08 2016-12-13 Ludwig Institute For Cancer Research Ltd TGF-β1 specific antibodies and methods and uses thereof
RS61778B1 (sr) 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
ES2860952T3 (es) 2013-08-01 2021-10-05 Univ Catholique Louvain Proteína anti-garp y usos de la misma
WO2016089950A1 (en) * 2014-12-04 2016-06-09 Beth Israel Deaconess Medical Center, Inc. Cancer therapy targeting intercellular adhesion molecule 4 (icam4)
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
WO2016115345A1 (en) 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Treatment of cancer with anti-lap monoclonal antibodies
EP3770171A1 (en) 2015-04-03 2021-01-27 XOMA Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
WO2017023749A1 (en) * 2015-07-31 2017-02-09 Tarveda Therapeutics, Inc. Compositions and methods for immunomodulation
HRP20211081T1 (hr) 2015-09-15 2021-10-15 Scholar Rock, Inc. Anti-pro/latentna miostatinska protutijela i njihove uporabe
AU2017310027A1 (en) 2016-08-12 2019-01-31 Merck Patent Gmbh Combination therapy for cancer
TW201811827A (zh) 2016-09-05 2018-04-01 日商中外製藥股份有限公司 抗ＴＧＦ－β１抗體及使用方法
WO2018129331A1 (en) 2017-01-07 2018-07-12 Merck Patent Gmbh Dosing regimens and dosage forms for targeted tgf-b inhibition
EP3571227A1 (en) 2017-01-20 2019-11-27 Sanofi Anti-tgf-beta antibodies and their use
AU2018228435C1 (en) 2017-03-02 2025-09-18 National Research Council Of Canada TGF-beta-receptor ectodomain fusion molecules and uses thereof
MA49690A (fr) 2017-07-28 2021-05-19 Scholar Rock Inc Inhibiteurs spécifiques du complexe ltbp de tgf-bêta 1 et leurs utilisations
EP3694552A1 (en) * 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
US20210340238A1 (en) * 2018-07-11 2021-11-04 Scholar Rock, Inc. TGFß1 INHIBITORS AND USE THEREOF
MA53125A (fr) * 2018-07-11 2021-05-19 Scholar Rock Inc Inhibiteurs de tgf?1 sélectifs selon l'isoforme à affinité élevée
JP7654539B2 (ja) 2018-09-07 2025-04-01 ファイザー・インク 抗αｖβ８抗体、組成物及びその使用
CN113164766B (zh) 2018-10-23 2025-02-25 供石公司 RGMc选择性抑制剂及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019509737A (ja) * 2016-03-11 2019-04-11 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． ＴＧＦβ１結合性免疫グロブリンおよびその使用
WO2018129329A1 (en) * 2017-01-06 2018-07-12 Scholar Rock, Inc. ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FRONTIERS IN ONCOLOGY, vol. 9, JPN6025008405, 2019, pages 883, ISSN: 0005701211 *
JOURNAL OF THORACIC ONCOLOGY, vol. 13, no. 4, JPN6025008403, 2018, pages 521 - 532, ISSN: 0005701212 *
NATURE, vol. 554, JPN6025008407, 2018, pages 544 - 548, ISSN: 0005701210 *

Also Published As

Publication number Publication date
WO2021142448A2 (en) 2021-07-15
AU2021205440A1 (en) 2022-09-01
CA3166328A1 (en) 2021-07-15
WO2021142448A3 (en) 2021-09-02
EP4087659A2 (en) 2022-11-16
US20230050148A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
US20250257125A1 (en) HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF
US20250215072A1 (en) Isoform-selective tgfb1 inhibitors and use thereof
US20230050148A1 (en) Tgf-beta inhibitors and use thereof
JP7719779B2 (ja) ＴＧＦβ阻害剤およびその使用
WO2022204581A2 (en) Tgf-beta inhibitors and use thereof
EP4348260A2 (en) Tgf-beta inhibitors and therapeutic use thereof
US20250282857A1 (en) Tgf-beta inhibitors and use thereof
JP2026507882A (ja) 患者の抵抗性又は不応答性癌を治療するためのＴＧＦ－β阻害剤及びその使用
US20240294623A1 (en) Tgf-beta inhibitors and therapeutic use thereof
CA3105988C (en) High-affinity, isoform-selective tgf.beta.1 inhibitors and use thereof
EA049507B1 (ru) ВЫСОКОАФФИННЫЕ, СЕЛЕКТИВНЫЕ В ОТНОШЕНИИ ИЗОФОРМЫ ИНГИБИТОРЫ TGFβ1 И ИХ ПРИМЕНЕНИЕ
HK40025565B (en) Isoform selective tgfbeta1 inhibitors and use thereof
HK40025565A (en) Isoform selective tgfbeta1 inhibitors and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260403